Four major cancer institutes have joined Illumina to set up a program that helps oncologists diagnose, classify and treat cancer using next-generation sequencing. The Actionable Genome Consortium (AGC) brings together the San Diego–based sequencing giant with the Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center and Fred Hutchinson Cancer Research Center. The aim is to define genomic changes in patients' tumors that will allow oncologists to choose optimal therapies and testing strategies. The hope is that defining an 'actionable tumor' will support new diagnostics development and regulatory oversight for genomic testing in cancer.
Rights and permissions
About this article
Cite this article
Actionable Genome Consortium to guide NGS in cancer. Nat Biotechnol 32, 965 (2014). https://doi.org/10.1038/nbt1014-965d
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1014-965d